263 related articles for article (PubMed ID: 33619102)
1. Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site.
Matthew S; Chen QY; Ratnayake R; Fermaintt CS; Lucena-Agell D; Bonato F; Prota AE; Lim ST; Wang X; Díaz JF; Risinger AL; Paul VJ; Oliva MÁ; Luesch H
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33619102
[TBL] [Abstract][Full Text] [Related]
2. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.
Prota AE; Danel F; Bachmann F; Bargsten K; Buey RM; Pohlmann J; Reinelt S; Lane H; Steinmetz MO
J Mol Biol; 2014 Apr; 426(8):1848-60. PubMed ID: 24530796
[TBL] [Abstract][Full Text] [Related]
3. Insights into the interaction of discodermolide and docetaxel with tubulin. Mapping the binding sites of microtubule-stabilizing agents by using an integrated NMR and computational approach.
Canales A; Rodríguez-Salarichs J; Trigili C; Nieto L; Coderch C; Andreu JM; Paterson I; Jiménez-Barbero J; Díaz JF
ACS Chem Biol; 2011 Aug; 6(8):789-99. PubMed ID: 21539341
[TBL] [Abstract][Full Text] [Related]
4. Interaction of cryptophycin 1 with tubulin and microtubules.
Kerksiek K; Mejillano MR; Schwartz RE; Georg GI; Himes RH
FEBS Lett; 1995 Dec; 377(1):59-61. PubMed ID: 8543019
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of colchicine B-ring analogues tethered with halogenated benzyl moieties.
Cosentino L; Redondo-Horcajo M; Zhao Y; Santos AR; Chowdury KF; Vinader V; Abdallah QM; Abdel-Rahman H; Fournier-Dit-Chabert J; Shnyder SD; Loadman PM; Fang WS; Díaz JF; Barasoain I; Burns PA; Pors K
J Med Chem; 2012 Dec; 55(24):11062-6. PubMed ID: 23176628
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
7. Tubulin and microtubules as targets for anticancer drugs.
Hadfield JA; Ducki S; Hirst N; McGown AT
Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
[TBL] [Abstract][Full Text] [Related]
8. Ultrapotent vinblastines in which added molecular complexity further disrupts the target tubulin dimer-dimer interface.
Carney DW; Lukesh JC; Brody DM; Brütsch MM; Boger DL
Proc Natl Acad Sci U S A; 2016 Aug; 113(35):9691-8. PubMed ID: 27512044
[TBL] [Abstract][Full Text] [Related]
9. A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs.
Prota AE; Bargsten K; Diaz JF; Marsh M; Cuevas C; Liniger M; Neuhaus C; Andreu JM; Altmann KH; Steinmetz MO
Proc Natl Acad Sci U S A; 2014 Sep; 111(38):13817-21. PubMed ID: 25114240
[TBL] [Abstract][Full Text] [Related]
10. Structural Basis of Microtubule Stabilization by Discodermolide.
Prota AE; Bargsten K; Redondo-Horcajo M; Smith AB; Yang CH; McDaid HM; Paterson I; Horwitz SB; Fernando Díaz J; Steinmetz MO
Chembiochem; 2017 May; 18(10):905-909. PubMed ID: 28207984
[TBL] [Abstract][Full Text] [Related]
11. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery.
Wang Y; Zhang H; Gigant B; Yu Y; Wu Y; Chen X; Lai Q; Yang Z; Chen Q; Yang J
FEBS J; 2016 Jan; 283(1):102-11. PubMed ID: 26462166
[TBL] [Abstract][Full Text] [Related]
12. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
Tangutur AD; Kumar D; Krishna KV; Kantevari S
Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
[TBL] [Abstract][Full Text] [Related]
13. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
Bai RL; Pettit GR; Hamel E
J Biol Chem; 1990 Oct; 265(28):17141-9. PubMed ID: 2211617
[TBL] [Abstract][Full Text] [Related]
14. The discovery of novel indazole derivatives as tubulin colchicine site binding agents that displayed potent antitumor activity both in vitro and in vivo.
Cui YJ; Ma CC; Zhang CM; Tang LQ; Liu ZP
Eur J Med Chem; 2020 Feb; 187():111968. PubMed ID: 31865012
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of a new class of cryptophycins based tubulin inhibitors.
Kumar A; Kumar M; Sharma S; Guru SK; Bhushan S; Shah BA
Eur J Med Chem; 2015 Mar; 93():55-63. PubMed ID: 25647428
[TBL] [Abstract][Full Text] [Related]
16. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.
Jordan A; Hadfield JA; Lawrence NJ; McGown AT
Med Res Rev; 1998 Jul; 18(4):259-96. PubMed ID: 9664292
[TBL] [Abstract][Full Text] [Related]
17. Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains.
Naaz F; Haider MR; Shafi S; Yar MS
Eur J Med Chem; 2019 Jun; 171():310-331. PubMed ID: 30953881
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site.
Li L; Jiang S; Li X; Liu Y; Su J; Chen J
Eur J Med Chem; 2018 May; 151():482-494. PubMed ID: 29649743
[TBL] [Abstract][Full Text] [Related]
19. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
Du T; Lin S; Ji M; Xue N; Liu Y; Zhang Z; Zhang K; Zhang J; Zhang Y; Wang Q; Sheng L; Li Y; Lu D; Chen X; Xu H
Cancer Lett; 2020 Dec; 495():22-32. PubMed ID: 32931884
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of vinca alkaloids and phomopsin hybrids.
Ngo QA; Roussi F; Cormier A; Thoret S; Knossow M; Guénard D; Guéritte F
J Med Chem; 2009 Jan; 52(1):134-42. PubMed ID: 19072542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
